Biotechnology companies selling a single product into a market typically face one of three choices: send out a sales force with a single item in their portfolio, license it to a partner with an existing product line, or acquire a product line.

In the case of Genzyme Corp., the third choice was the obvious one. With FDA approval of its Seprafilm hyaluronic acid-based product to prevent post-surgical adhensions expected by July, the company has no other near-term surgical products, except the other members of its HA family. Next in line is Sepracoat, for which GENZ submitted a marketing application in January. While GENZ has other surgical products in early development, it hasn't discussed them publicly.